Advanced Enzyme Technologies Limited has announced strong financial results for the fiscal year ended March 31, 2026. The company reported a significant increase in annual revenue to ₹7,457.57 million and a net profit of ₹1,736.08 million. In light of this performance, the Board has recommended a final dividend of 67.5%, equivalent to ₹1.35 per equity share, subject to shareholder approval at the upcoming 37th Annual General Meeting.
Financial Performance Overview
For the financial year ended March 31, 2026, the company delivered solid growth. Total annual revenue from operations reached ₹7,457.57 million compared to ₹6,369.10 million in the previous year. The consolidated net profit for the year stood at ₹1,736.08 million, reflecting a healthy upward trajectory from ₹1,339.74 million reported in the prior fiscal period.
Dividend and Strategic Capital Allocation
The Board of Directors has recommended a final dividend of ₹1.35 per equity share (67.5% on a face value of ₹2), pending approval from shareholders at the 37th Annual General Meeting. Additionally, the Board has decided to defer any interim dividend declaration at this time. The company intends to prioritize capital preservation to maintain liquidity and pursue future strategic avenues to maximize long-term shareholder value.
Leadership and Governance Updates
As part of its governance, the Board has approved the re-appointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for a new 5-year term effective April 1, 2027. Furthermore, Mr. Pradip Bhailal Shah has been appointed as an Additional Director (Independent) for a 5-year term effective June 12, 2026. M S K A & Associates LLP has been re-appointed as the company’s Statutory Auditors for a second term of five years.
Allotment of Equity Shares
Pursuant to the Employee Stock Options Scheme 2022, the Board approved the allotment of 49,350 equity shares of face value ₹2 each. This action increases the company’s paid-up share capital to ₹22,39,52,300, consisting of 11,19,76,150 equity shares, with the newly allotted shares ranking pari-passu with existing equity.
Source: BSE
